Antiretroviral Analytical Treatment Interruption (ATI) to Assess Immunologic and Virologic Responses in Participants Who Received VRC01 or Placebo and Became HIV-infected During HVTN 704/HPTN 085
Latest Information Update: 13 Aug 2024
At a glance
- Drugs VRC 01 (Primary)
- Indications HIV-1 infections
- Focus Adverse reactions; Therapeutic Use
- 09 Aug 2024 Status changed from active, no longer recruiting to completed.
- 27 Jun 2023 Status changed from recruiting to active, no longer recruiting.
- 13 Jan 2023 Planned End Date changed from 29 Jun 2023 to 10 Jan 2030.